Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Amyotrophic Lateral Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 81 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AB Science
- Last updated on ClinicalTrials.gov
- September 12, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
California · 1
- University of Southern California · Los Angeles, CA
Kentucky · 1
- University of Kentucky · Lexington, KY
Maryland · 1
- Johns Hopkins Medicine Brain Science Institute · Baltimore, MD
Massachusetts · 1
- Lahey Hospital and Medical Center · Burlington, MA
Virginia · 1
- University of Virginia Health System · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.